Dimensional Fund Advisors LP Buys 23,714 Shares of Bausch + Lomb Co. (NYSE:BLCO)

Dimensional Fund Advisors LP increased its stake in shares of Bausch + Lomb Co. (NYSE:BLCO) by 53.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,690 shares of the company’s stock after buying an additional 23,714 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Bausch + Lomb were worth $984,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of BLCO. Invenomic Capital Management LP bought a new position in shares of Bausch + Lomb during the 1st quarter worth approximately $6,817,000. Rokos Capital Management LLP bought a new position in shares of Bausch + Lomb during the 1st quarter worth approximately $5,602,000. Whitebox Advisors LLC lifted its position in shares of Bausch + Lomb by 29.3% during the 1st quarter. Whitebox Advisors LLC now owns 1,206,303 shares of the company’s stock worth $20,869,000 after buying an additional 273,484 shares during the period. Fore Capital LLC bought a new position in Bausch + Lomb in the 1st quarter valued at $384,000. Finally, Quadrature Capital Ltd raised its position in Bausch + Lomb by 75.8% in the 4th quarter. Quadrature Capital Ltd now owns 48,258 shares of the company’s stock valued at $824,000 after purchasing an additional 20,803 shares during the last quarter. Institutional investors own 11.07% of the company’s stock.

Insider Buying and Selling

In other Bausch + Lomb news, CEO Brent L. Saunders bought 32,250 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was purchased at an average cost of $15.66 per share, with a total value of $505,035.00. Following the completion of the purchase, the chief executive officer now owns 595,169 shares in the company, valued at approximately $9,320,346.54. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.15% of the stock is owned by insiders.

Bausch + Lomb Stock Up 1.8 %

Shares of Bausch + Lomb stock opened at $19.47 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.65 and a debt-to-equity ratio of 0.70. Bausch + Lomb Co. has a 12 month low of $13.16 and a 12 month high of $21.00. The business has a fifty day simple moving average of $17.19 and a 200 day simple moving average of $16.00. The stock has a market cap of $6.85 billion, a PE ratio of -14.98, a price-to-earnings-growth ratio of 1.76 and a beta of 0.48.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.13 EPS for the quarter, hitting analysts’ consensus estimates of $0.13. Bausch + Lomb had a positive return on equity of 3.36% and a negative net margin of 10.15%. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the firm earned $0.18 earnings per share. The firm’s quarterly revenue was up 17.5% compared to the same quarter last year. Research analysts predict that Bausch + Lomb Co. will post 0.6 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Evercore ISI lifted their price objective on Bausch + Lomb from $17.00 to $19.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Stifel Nicolaus lifted their price objective on Bausch + Lomb from $16.00 to $19.00 and gave the company a “hold” rating in a research report on Monday, September 23rd. Raymond James assumed coverage on Bausch + Lomb in a research report on Wednesday, July 10th. They issued an “outperform” rating and a $19.00 price objective for the company. Evercore lifted their price objective on Bausch + Lomb from $15.50 to $17.00 and gave the company an “in-line” rating in a research report on Thursday, August 1st. Finally, HC Wainwright lifted their price objective on Bausch + Lomb from $19.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.45.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.